listening Thank you thanks Amol, in. everyone for much, and very
also companies agenda full progress about the and an but that primarily and year today certainly QX the our inside and to talk and the the both strategy going opportunity. talk that around financial of about highlights build execution I'm our vision of and I’ve strategic we'll aspiration
about specifically financials XXXX. key talk will our time that through look detailed for to Q&A. at we’ll also goals up for more some then open place going are bit spend and our a several Amol in little catalysts We’ll growth in
Before been last of getting lot news Quanterix. in of regarding starting lot there the weeks couple impact coronavirus has the of we've a the of a questions been and on
the Our is around health world. and our concern top well-being our of employees
on for monitoring team We latest have executive had place a the with situation. developments. our in to force top stay the several weeks meet of regularly task We
situation has of major impact As today the on not operations. had a our
developments should is support latest team situation day of And China. in and necessitate communication plans XX% contingency of the steps the the Asia commercial field and We're only way from those to operations. assure from also the of customers further also deteriorate just supply. closely to with about revenue develop continuing comes some of our comes and contingency X% which plans. financials following Our we're We've our taken of day to regular continuity CDC in from
close QX. and impact COVID-XX Only that comment of we enter and portion continued seen as a instrument have consumable we QX so spread the supply comes revenues, while revenue global we services if impact out didn’t be minimal on negligible of our remiss and would and Italy placements our the from far we revenue could
operations, situation a and as customers short-term continue on positive we long-term is for as disruption, This is our to remain proactively our and well the on the employees, obviously factors some fast-changing of there underlying investors. mitigate will we potential business. impact the growth While very business
the of biomarkers the just every but type then, start publications and for our category full rapid a well they now shows cross are blood, measured in ramp Slide briefly that, on the about that like as to do being sample that in quarter with the So customers our body. from I'd year, by X primarily as human
QX about We our also you we'll also and which launch that see also fact, we strong and that this in very of revenue strong HD-X. full-year QX in XXXX did, growth growth What's our a at growth $XX.X our launched QX are out is XX% this SP-X. can augmented did and We deliver exciting margin very while got been the slide early what we advance, has compelling revenue led on show, XX% by and most that shown to gross in a million. growth we
had grew actually built full-year favorable some growth consumable very opportunities it year-on-year. nearly XX% we onetime, Our and where
aspirational gives We give us the which growth able opportunity it also were and well to sheet thought strong manage million uncertainties ahead very as that us capital of balance $XXX mass of some were as compelling - growth we any interesting was opportunities. a us and to pretty important raise for
acquiring to for to Siemens And it IVD our and provided also Uman asset. the acquire an X that company. after bought We seen it July and we've did defense offense license make technisource interesting of We close initially with of to able Nf-L antibody license we Nf-L opportunities We an industry on that were supply very licensed standard. for Uman now but deal. some
strongest company. of our our further publications ECTRIMS the year AAIC people as XX namely as to team of to to one this past biomarkers. the counsel Amol, really as important this, portfolio was some as neural added our the well augmenting general our job, evolve We well strength progress We also this showing at year had of continue
We Clinical that Vice opportunity emerging. see of Biomarkers as we also President Senior new Tatiana this our recently given Plavina named
consumable see see bps growth you on we had very advance And can can of XXX QX margin basis So strong Slide that is gross on of an very had X which also adjusted XX%. we compelling. we
is launched products indicator leading past growth. which of overall year XX% which really which our this we a created the with year significant great is that for future also surge a We grew revenue instrument nice surge, a two
the this Given revenue of greater is overall that pull consumer grown than now past through having year. our XX% mix, XX%
our just we the various with illustrate X, Slide accelerator. on revenue the components of So starting
You our need there trials, there the We've is our see full trial in important This protect drug us we've of drug Accelerator continued we to been can services growth projects lab. and any on has to Having now create Laboratory, a and backlog very changeover growth given are nice very XXX done may our the significant. strong lab. to for our of as customers it us just many the of going strong the greater we growth surge utilizing right implications base forward. seeking of our seeing overall a now visibility are backlog much and trajectory out of growth strong gives services really instruments installed year
replacements XXX by instrument we've And then can you year see reached end. the
both have as MS they primarily for have about drug million going of associated - revenue, instrument our years see growth for XX% see that some was growth also nearly two last Nf-L of a that seen that which may trial, they in and QX you with from $X announced our year Novartis week and consumable We the approval they're with the you which years previous last surrogate last three step can the to believe could strong level been endpoint. utilized of secondary the a onetime the years up major XXXX surge you
is there will They that role of XXXX, approval on see played the even of can And we pretty you gross more which slide. in June is right hand exciting the margin exciting. have side believe rapid ascent they than the the
what we consumable that of category, and percent in up total the for but around to last would XX dollars the on this and three now state do the the we’ve couple years stepped XX%. consumables we sell things and I the were is it's is slide years of of been One annually at that running we've last of about base total instruments for installed at XX% XX dollars running sold utilization those
So, up step kits is greater by instruments to that more our that supply have and the throughput. menu expanding, homebrew evolving better just than coming
just revenue. the demographics of X our illustrates Slide
now creating can faster we're better so or has factors elicit been greater it's America try launching - academia faster and form publication balance smaller to us You several either XX/XX could growth from primarily last primarily which you see product been growing because Asia that wise growing but longer we're We the we're pharma primarily see academia customer help North we've term. a about to Europe quarters the but in we're academia.
giving growth good And our oncology consumables see past now now very launched future us strongest you had can be strong in for a represents some expecting oncology continues XXXX. of revenues. perspective to to from and see mix overall growth year finally growth visibility this And XX% from now neurology nice so really just mix the we we're then we into
disease spinal that's the many at and symptoms require briefly still seeing for see times neurology just or real move that company much take value disease proposition stage order that the to to diseases able disease when cycle in disease cancer ability today is noninvasively the be and get state. in to late like earlier particularly it look and oppose to strategy. tap very our I'd in now surgery before sample and long to is So in a see to blood the to to and The treatable
that healthcare exquisitely and transformative basically the technology represents digital our sensitive. earlier these as consider to it we be and is seeing opportunity that with So when you blood biomarkers technology combine enable much forming
just when throughout the expresses have there that protein X and grow shows Primarily, They that born, live that cause be same twins might up. changes they're identical environmental there's but different lives. factors Slide are way DNA they things phenotypic it's of as lot the life. their a their differently - exact they protein the to in
these actually disease. environmental lot of creates trigger what a factors And
then proteomics honed digitizing and revolution to on by And whole try exquisite opportunity and sensitivity. so, protein a the really creating see we've it with instill proteomics the to
traditional iceberg we like XXX would MSD, Siemens, can XX IBD just are about can bottom, moved Techne X,XXX from diagnostics, see capability and some true you that levels analogy where also be that Quanterix that the of for historically illustrates, at And into per show nanogram overall. above that show the Roche the Luminex, have you measured But have measure ml. to companies Abbott here, we picogram about that ProteinSimple at plays. Slide down here, to proteins that see
able that's sensitivity really we today's opportunity protein we of femtogram more of aren't it's think blood our enabling. X,XXX, X,XXX to proteins IBD. that that in an X be per level XX,XXX that's And sensitive, over about that IBD maybe the times represents And There's nearly approved into today. measured circulate times think ml
human. So, biomarkers bar yellow And the when traditional in that some to of important in vertically level at right-hand level, side, farthest the the the those which on healthy, bar horizontal and And really just would goes most we green lowest that then the you're be you're level. show particular the today's the we've showcased of detection biomarkers shows left. to
the on biomarkers. diseased you them on red healthy as see LoD these The then to when biomarkers. really what critical see differentiates ability to these it critical ability And as our Quanterix’s can you're well when being achieve you're is
We’re X,XXX average. times more sensitive on
So it's a differentiate ourselves. to way real key
the next diseases. illustrate Alzheimer's slide diseases. slide that true there's the no way that very of in cancer and treat it's far cancers that typically sometimes we’ve many we brain stage, are for lung to a many CTE those with this particularly presentations neurology or to and along is X And pancreatic cancer late cancers degeneration previous the so like and is of used neuro Same in good s find neuro Stage in and
don't until have them symptoms symptoms time stage. very and by you you have detect late Sometimes you they’re
in be a lower see So that requires spinal biopsy nearly detection. to got earlier not And to see in allows levels concentrations be ability see very we've use to publications or disease what you protein also you you could an less blood neurology create XXX cancer, now proteins to in invasiveness low actual that requires of surgical tap. able to earlier that see and able low disease it to in but to same at XXX see only invasively the the that
have years we to four, don't no reimbursement begun have believe business just that research and we XXXX. grown XX basically in Slide have low five multiple from like million a risk growth execution a regulatory do drivers. we to an deliver we to from where this on in continue machine to category So risk we illustrate ago revenue or $XX We've opportunity the
the And actually with has technologies since nine grow probability trajectory growth the public increase quarters The into approved. in investors our their that - investors the companies. and helping of which last to investments doubled gone support lot a their are the is helping technologies incorporated most be companies going in for companies, get of because we've drug drug us is drug our our our - that of something developed have helped that invested must those want
most aspirationally on market to But ago, that's diagnostic and on the little the the an size opportunity times we right-hand regained all over importantly of rights year see side, a we enter market left, does XX our does require probably a from side into a risk side. research into regulatory the we trying approvals right-hand and a do that's that left-hand manage that can the year, and have reimbursement and study the this more carefully and we're move start so to something way to measure of
opportunity this as blood strategic calling And ideas we is a we pretty disease see by can before be liquid the a could have of way ability biopsy some as well MRI, significant year into do how health neurology end, it, to hope long to liquid brain disruption practiced. and we're good but to game-changing that tap in the further to
next just the This slide on side. market the show in left you the execution
that, less XX% we're penetration market. SP-X, today, the the play we see primarily than more in product, is that $XXX have in we But penetration market is billion. million almost to billion into can we market onco, X% with neuro of $X like where million You have which newer And where $XXX $X the market. now moving that
of side, excitement on And can this our some mainly neuro-disruptive estimate that players strategic volley we are we of the see in you first be and can could for right-hand which and our of our pathways is Luminex built HD-X a MSD, think see $X the diagnostics, articulation we are but being opportunities as diagnostics. as as and over evolve billion, large year SR-X into clinical this into you
of that and is accelerator sell we year-end actually XX, all summarizes consumables launch kits instruments. the which early HD-X which on were XX then We on incenting assay hurts to margins we have last that consumables service franchise, year. that fast trade largest more through, but by were is next in which place franchise we The HD install they the slide, customer we higher the And we just trade-ins their a those HD-Xs. is Slide very which are lot this pull lab of going HD-Xs sell surge. help margins long-term because where the in margin eliminate and actually short-term are investments HD-X to to right. way with the the We our able need Half field is HD-Xs the a left, the
SR-X year can enhanced gives new point. the the and consumable about the also by We of trade-ins be again, nearly will HD-installed greater of think will in actually XXX launched that drug for yet, our which its estimate HD-Xs. sales capabilities ability base we at drugs get the we of the have cohorts approved to trials, dosing toxicity the into earlier now LDT and important effective help drug for lower by disease was recruiting SP-X those demonstrate symptomatic the accelerator when as to and and affected isn’t cancer be price potential even that And which year-end better XXXX, XX/XX This for will CLIA Then versus lower and we SP-X, be $XXX,XXX is that disease. this sensitivity half to be economics. because you technology the and easier direction see past
any the low to sensitivity a smaller a ability answer markers enables just sample. you you gives It’s next the detection, slide allows This but shows just early from things. to of abundant lot not see see
accuracy. can You better dilute for up
sensitivity. disease campaign multiple And to all future of beginning gives better suffering the because create uncover. elimination gives also it proteomics markers proofing without you the you ability the these simultaneously specificity that multiplex markers It new of to to are
see invest And that. think and today, can deployed on in we we'll you to proteins actually be want samples of seen side achieve see sensitivity levels our right another spinal require hand sensitivity to hundred we sensitivity in will the can to is fluid it that extra because the continuing when greater like and blood we're someday cerebral
about that excited pretty advance. we're So,
just on like own our in now X And there’s facilities the you instruments biomarkers. the CROs industry approval right This shows improvement LabCorp at Slide toxicity the now XXX% ability if a there's get next XX XX the approval you're a our medicine from drug using could Quest and and challenges services. drug Frontage that see and in XXX Phase X Phase and and efficacy trials of rules-based and even there to Eurofins and has and the and been these
whether health cost suicides patients in ramp in The rapid caused that the that drugs it’d homed next biomarkers issue the XX the be mental and we projected that's or to from burden on neurology predicted Alzheimer stress guidance shows creating all of opioid very have disorder that's approved. soldiers FDA the is America or the help their have get use post-traumatic or is slide day being addiction that to a up large issues a FDA to and the
starts The today see or are you And drugs you either using that all it technology slide - can't XX. next the really but see support research it's up now help starts approved. companies to in builds our it that XX can to buildup a slide and
we're the you by into us these - evolving of starting three Illumina enable maybe feel these As diagnostic sciences landscape. the the exact order platform neurology right in opportunity the technologies illustrates to platform the deep and of become the brain value care. And into rich best hand dive we we way can or ways compelling biopsy our think point side in to aspirational liquid to a migrate biopsies of areas XX Slide the do have on we of many to that a for that value liquid proposition company, we understand see somewhat strategically that a could liquid creation
you ramp-up neurofilament trials illustrate using light. our the To that, drug of shows XX Slide just rapid
You patients our points. utilizing works against Nf-L diseases Nf-L And like the see far Nf-L currently clinical III can trials MS there ALS. the you Nf-L. thus X,XXX trials disease, trials there's surrogate Phase the that also Alzheimer's, five using our other TBI, were end XXX There's Then side, can primarily see currently as XX secondary on using right-hand across Nf-L. nerve
seeing to pairs but by that us it in very it And to right-hand can all as we Uman Slide XX, Uman makes to the specific and And past, on us gave for the greatness other for very we've and combination Nf-L this had supply with protect to blood-based our based years has you antibody that to somebody an and on than the next franchise, advantage sensitive. are The that that got very publications pair, looked in-house the sensitivity, been antibody allow also our to of illustrates exquisite was XXX as grow our three the company which it. shown see nobody but well specific now able antibodies, side, Simoa. find buy Uman liquid
placebo they either time is showing total a this multiple that using you two in cohorts Slide existing completed, to total that effect even This the weeks. meetings and you meaning is we're drug. grow. clinical studies an investor observational XX, those Nf-L, interventional, continuing them they’re the Nf-L a XXX. first can some measuring the last the follow-up are that actually had have this illustrated two versus some active or we of And We there's is from and of And shows see or are
The you category and middle see X that and can X the our different cut can penetration. right those the diseases. also see all X, take that category when in X see X% those three in current across see blue our diseases they you Phase key trials different the now the how than actives, can particular the you are the then can trials XX from neuro the light that you is the represents neuro In three Then and less we over to categories. penetration across
officers how we've been we're big a and field So trials of slides using better this to is our lot dimensions linking customers further get of try penetration with with up working in set to by our the in is chief opportunity the that actual a articulate this neurology of our teams key medical that to sales just framework. Nf-L our
be as today worth which just MS or patient already life Novartis the on mentioned difference shows the whether keep the the drug is approved billion. them for way XX get rapidly very are MS that expectancy same Slide for XX that dying which an can your can dying right wheelchair like patient be Nf-L between an standing drugs drug next trials MS it you drug because disease This we've $XX in in is for drug. for the a to with And up. selection best there versus
on MS working on try the this difference illustrates an FDA of to evidence evidence trials there's year. of between one going advance this drug working and the of and can is There's MRI a using to biology a into with patient. we're there opportunity meeting to now clinic within is the an that also impact disease X.X create for to that see going lot the trials a see first if The these one that the is as months drug here three you
users Slide XX different be different XX The be soon FDA. we for for in a on is that the to labs, shows analytical same trials. results next this validity the customers. across Over two publication able different were key where get will One
so, now says die XX going we clinical And as across in there's large age. that it MS, of XXX that healthy create you're could data neuronal or damage Europe which get that or above then measure there's But until and hand be XX,XXX that moment ages that see it’d to already from degeneration healthy study can their samples even FDA. harm's way, Nf-L validation line, can be the are would because been right if for from what to the equal people on older concussions your XX on control with to ages see whether you the that Alzheimer's the being you there's neurons important side a levels an something nerve be XX,XXX putting run Parkinson's in you up
So, be continue key key By Slide us. also yearend with going We're goals to half consumable for that various utilization our presence. neurology will have we'll of for penetrating of in the XX We're the XXXX. installed expanding VHDX’s. and illustrates HDX them Asia-Pac high base
oncology, On we that SPX. new got
are We immune our treat I'm to SPX and immune profiles grow technology primarily assay = could cancer where adding immuno to neuro rate assays at XX and help - sorry on get and the the better treatments. you're looking system the scientists for at cancers
opportunistically From M&A. to prospect to long And growth this a a IVD do partnership term land continue XX% top line the strategy we'll standpoint, looking over growth. years three we're year. financials we an continue to also XX% And of looking for see
to services any we and mix overall a so first advance continuing are little continue half the growth see made over in R&D-wise, expect in growth growth changes to revalidate will but first mix as of HDX for The this the because to base be services and the year to up don't answers get through instruments and the coming margin us XXXx instrument rates sensitivity. they're we half and a to our evolution shift from bit growth a we of do to strong customers consumables our slower the installed our just see of and and shift
have the flawlessly as category-defining we every the Slide as operating to feel technology. So a we quarter, years X.X execution side, way aspirational side, from XX quarter-on-quarter annual summary, somewhat growth. in We've for the now well growth showing all been
market diagnostics, into which best-in-class low sensitivity, research the to in our up there’s risks we're but pharma way very the in relationships a market big a So we coming those. both and rivaled a and use think we very navigate have higher is to risks are with where
market now there think over very pharmas. this we Health top sponsor XXX third-party reviewed are the all of we a drug validation, peer of, them point. This all Precision have We've top that them. at we're summit, strong a over this from So XX got of perspective, pubs XX Power And then trials these to XXX opportunity.
this to visibility commercialization in a with as from we standpoint the through, has evolution risk - and a to experience consumable and commercialize penetration our have management a much board really gives team a us. also had great reward lot pull We better continue very strong an penetration of that incredible
over Amol, like first around it XXXX. now for back So financial you - to our our some our quarter to turn I'd full of fourth discussion year and
